Bio Rad Laboratories Inc
NYSE:BIO
Bio Rad Laboratories Inc
Cash & Cash Equivalents
Bio Rad Laboratories Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bio Rad Laboratories Inc
NYSE:BIO
|
Cash & Cash Equivalents
$433.3m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
2%
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cash & Cash Equivalents
$5.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
38%
|
CAGR 10-Years
14%
|
|
Danaher Corp
NYSE:DHR
|
Cash & Cash Equivalents
$7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cash & Cash Equivalents
$70.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-5%
|
|
Agilent Technologies Inc
NYSE:A
|
Cash & Cash Equivalents
$1.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-6%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cash & Cash Equivalents
$1.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
See Also
What is Bio Rad Laboratories Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
433.3m
USD
Based on the financial report for Mar 31, 2024, Bio Rad Laboratories Inc's Cash & Cash Equivalents amounts to 433.3m USD.
What is Bio Rad Laboratories Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%
Over the last year, the Cash & Cash Equivalents growth was -7%. The average annual Cash & Cash Equivalents growth rates for Bio Rad Laboratories Inc have been -14% over the past three years , -1% over the past five years , and 2% over the past ten years .